
II Research Grant in Oncology ASEICA + QUEUNTRAIL · Alcoi
ASEICA and + QUEUNTRAIL · Alcoi deliver the II ASEICA & + QUEUNTRAIL · Alcoi Aid to cancer research projects. The financing of this aid of 20,000 euros goes to the project of Dr. Verónica Rodilla Benito, from the Josep Carreras Leukaemia Research Institute entitled: “Monitoring senescence upon chemotherapy (MonSen)”, and was delivered during the 17th ASEICA International Congress which, due to to the current situation, it was carried out virtually on November 4, 5 and 6.
The Spanish Association for Cancer Research (ASEICA) and + Que un Trail launch for the second consecutive year the call for the II ASEICA & + QUEUNTRAIL · Alcoi Aid.
With an endowment of 20,000 euros, this aid aims to promote a line of research in cancer directed by an independent Researcher in the process of consolidation within a University, Health Institute or Research Center.
You have until October 12, 2020 to participate.
For more information, consult the bases of the call or contact the ASEICA technical secretariat [93 451 17 24 – secretaria@aseica.es].



I Ayuda de Investigación en Cáncer FERO-ASEICA
The FERO Foundation and the Spanish Cancer Research Association (ASEICA) deliver the 1st FERO-ASEICA Aid to cancer research projects. The financing of 80,000 euros goes to the project of Dr. Cristina Mayor-Ruiz, from the Institute of Biomedical Research (IRB Barcelona) entitled: “Targeted Protein Degradation: drug discovery innovation for cancer treatment“, and was delivered during the 17th ASEICA International Congress that, due to the health situation, was held virtually on November 4, 5 and 6.
This research aid, which has an amount of 80,000 euros, wants to meet two fundamental objectives. On the one hand, promoting the careers of young scientists who have recently established their independent research groups. On the other hand, to favor the realization of cutting-edge research in cancer that, ultimately, allows promoting the rapid transmission of advances in cancer knowledge for the benefit of cancer patients in terms of diagnostic and therapeutic improvements.
The request will be made in 2 independent phases.
Deadlines:
• Launch: June 2
• Phase 1 closure: July 1
• Short List with Proposals: July 28
• Full Proposed Petition: July 29
• Phase 2 closure: September 15
• Researcher selection for Help: September 30-October 15
• Delivery Aid: November 6, 2020 at the XVIII ASEICA International Congress



Application for research aid in ASEICA Oncology & +QUEUNTRAIL Alcoi
ASEICA invites you to participate in the CALL FOR RESEARCH SUPPORT IN ASEICA ONCOLOGY & + QUEUNTRAIL·Alcoi.
The purpose of this aid is to promote a line of cancer research led by an independent researcher in the process of consolidation within a University, Health Institute or Research Centre.
You can participate until 30th September 2019. For further information please check the terms and conditions or contact ASEICA’s Technical Secretariat [93 451 17 24 – secretaria@aseica.es].
CANCER RESEARCH AID
At the 16th ASEICA International Congress that was held in Valencia on 6-8th November, ASEICA awarded its Cancer Research Aid to the following winners:
ASEICA AID: €30,000
Dr. María Jesús Vicent, Príncipe Felipe Research Centre, Valencia
Title: Identification of New Biomarkers and Development of Polymer-based Combination Conjugates in Metastatic Prostate Cancer

ASEICA YOUNG RESEARCHERS AID: €15,000
Dr. Ruth Rodríguez Barrueco, University of Barcelona – Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona
Title: New therapeutic targets based on abnormal glycosylation in breast cancer stem cells

ASEICA-SEOM AID: €15,000
Dr. Héctor Peinado Selgas, CNIO
Dr. Antonio Calles Blanco, Gregorio Marañón General University Hospital, Madrid
Title: Neoantigen detection in tumour exosomes obtained from peripheral blood of patients with microcytic metastatic lung cancer


DOMINGO MARTINEZ FOUNDATION-ASEICA AID: €30,000
Dr. Silvia Calabuig, General Hospital of Valencia Research Foundation
Title: Metabolomic analysis of the hypoxia-hyperoxia transition in 2D and 3D models in vitro in non-small cell lung cancer derived from patients.

